By Date


  • 16-janvier-2017

    Français

    Une nouvelle approche s’impose face à la hausse des prix des médicaments

    La multiplication de médicaments très onéreux et la hausse des prix des médicaments sont à l’origine de pressions de plus en plus lourdes sur les dépenses publiques de santé, et conduisent à remettre en question les stratégies tarifaires de l’industrie pharmaceutique.

    Documents connexes
  • 16-January-2017

    English

    People at the Centre: The Future of Health - opening remarks at 2017 OECD High-Level Policy Forum

    People-centeredness means treating people, patients, their loved ones, carers and others with compassion, dignity and respect. It means involving them in decision-making about their health and their care. It means doing things ‘with’ people, not ‘to’ them. It means involving people in system design and in policy making.

    Related Documents
  • 16-January-2017

    English, PDF, 1,422kb

    Patient-Reported Indicators Survey: Booklet

    Patient-Reported Indicators Survey: Explanatory Booklet

    Related Documents
  • 16-January-2017

    English, PDF, 1,816kb

    Recommendations to OECD Ministers of Health from the High-Level Reflection Group on the Future of Health Statistics

    Recommendations to OECD Ministers of Health from the High-Level Reflection Group on the Future of Health Statistics: Strengthening the international comparison of health system performance through patient-reported indicators.

    Related Documents
  • 16-January-2017

    English

    New Health Technologies - Managing Access, Value and Sustainability

    This report discusses the need for an integrated and cyclical approach to managing health technology in order to mitigate clinical and financial risks, and ensure acceptable value for money. The analysis considers how health systems and policy makers should adapt in terms of development, assessment and uptake of health technologies. The first chapter provides an examination of adoption and impact of medical technology in the past and how health systems are preparing for continuation of such trends in the future. Subsequent chapters examine the need to balance innovation, value, and access for pharmaceuticals and medical devices, respectively, followed by a consideration of their combined promise in the area of precision medicine. The final chapter examines how health systems can make better use of health data and digital technologies. The report focuses on opportunities linked to new and emerging technologies as well as current challenges faced by policy makers, and suggests a new governance framework to address these challenges.
  • 10-January-2017

    English

    Reviews of National Health Care Quality

    OECD Health Care Quality Reviews seek to examine what works and what does not work in different countries – both to benchmark the efforts of countries and to provide advice on reforms to improve their health system.

  • 10-January-2017

    English

    Tackling Wasteful Spending on Health

    Following a brief pause after the economic crisis, health expenditure is rising again in most OECD countries. Yet, a considerable part of this health expenditure makes little or no contribution to improving people's health. In some cases, it even results in worse health outcomes. Countries could potentially spend significantly less on health care with no impact on health system performance, or on health outcomes. This report systematically reviews strategies put in place by countries to limit ineffective spending and waste. On the clinical front, preventable errors and low-value care are discussed. The operational waste discussion reviews strategies to obtain lower prices for medical goods and to better target the use of expensive inputs. Finally, the report reviews countries experiences in containing administrative costs and integrity violations in health.
  • 21-December-2016

    English

    Pharmaceutical Pricing Policy project

    The policy study published by the OECD is based on six case studies, an extensive review of the literature, and analysis of relevant data. The report provides context for the analysis of pharmaceutical pricing policies in OECD countries, describes pricing policies employed by the OECD zone and assesses their impact.

  • 21-December-2016

    English

    Value in Pharmaceutical Pricing

    The Working Paper sheds light on the extent to which “value” is considered in pricing and/or coverage decisions in 14 OECD member countries. It describes methods used by countries to assess the therapeutic benefits of new products, as well as approaches for economic evaluation, where relevant, and aims to illustrate how value is assessed and what is its impact on pricing and/or reimbursement decisions.

    Related Documents
  • 5-December-2016

    English

    Life Annuity Products and Their Guarantees

    This publication helps policy makers to better understand annuity products and the guarantees they provide in order to optimise the role that these products can play in financing retirement. Product design is a crucial factor in the potential role of annuity products within the pension system, along with the cost and demand for these products, and the resulting risks that are borne by the annuity providers. Increasingly complex products, however, pose additional challenges concerning consumer protection. Consumers need to be aware of their options and have access to unbiased and comprehensible advice and information about these products.
  • << < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 > >>